source
- Darolutamide with ADT cuts death risk by half in metastatic hormone‑sensitive prostate cancerA recent study evaluated darolutamide combined with androgen deprivation therapy in patients with metastatic hormone‑sensitive prostate cancer. The trial reported a 50% reduction in the risk of dea…
- FDA approves adjuvant atezolizumab for MRD-positive muscle-invasive bladder cancerThe U.S. Food and Drug Administration has granted approval for adjuvant atezolizumab in patients with muscle‑invasive bladder cancer who test positive for circulating tumor DNA, indicating molecula…